Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial

por Tarcha, Eric J., Olsen, Chelsea M., Probst, Peter, Peckham, David, Muñoz-Elías, Ernesto J., Kruger, James G., Iadonato, Shawn P.
Publicado 2017

Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults

por Amberg, Sean M., Snyder, Benjamin, Vliet-Gregg, Portia A., Tarcha, Eric J., Posakony, Jeff, Bedard, Kristin M., Heald, Alison E.
Publicado 2022

Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis

por Land, Judith, Lintermans, Lucas L., Stegeman, Coen A., Muñoz-Elías, Ernesto J., Tarcha, Eric J., Iadonato, Shawn P., Heeringa, Peter, Rutgers, Abraham, Abdulahad, Wayel H.
Publicado 2017

Lassa antiviral LHF-535 protects guinea pigs from lethal challenge

por Cashman, Kathleen A., Wilkinson, Eric R., Posakony, Jeffrey, Madu, Ikenna G., Tarcha, Eric J., Lustig, Kurt H., Korth, Marcus J., Bedard, Kristin M., Amberg, Sean M.
Publicado 2022